Alcon Inc. · ALC · FY2025 Q2 · Calendar Q3 2025

Alcon lowers guidance as surgical demand softens

Alcon's longer-term product and portfolio expansion remains intact, but the latest call shifted the near-term balance toward softer surgical demand, tariff pressure and execution risk.

Why did ALC fall 10.1% after beating EPS estimates in FY2025 Q2?

Research this report with FN2. Free to start; review your question before sending.

Reported After market closeNYSEHealthcare $31.37B market cap
100quality score

Earnings scorecard

Reported versus consensus
Reported EPS $0.76 Consensus $0.71
EPS surprise +7.0% Reported versus consensus
Reported revenue $2.60B Consensus $2.65B
Revenue surprise -2.1% Reported versus consensus
Check the math in the surprise calculator >

Market reaction

event-close to next-session close
Stock move -10.1% Event window
SPY move -0.3% Same window
Abnormal move -9.8% Stock minus SPY
Volume 4.9× Versus trailing sessions
Subsequent drift -4.0% Up to 20 sessions
ALCSPY benchmark

Ask FN2 about ALC FY2025 Q2

Choose a question to continue your research

Free to start. Your question opens in chat for you to review and send. FN2 can look up the transcript, financials and prior quarters.

Transcript intelligence

What changed

Compared with the prior quarter, management moved from raised to lowered guidance. The current analysis emphasizes weaker surgical growth, higher expected tariff headwinds and the planned STAAR and LumiThera transactions, while new-product ramps remain central to the growth case.

Guidance delta

Guidance was lowered to $10.3-$10.4 billion of revenue, 4%-5% constant-currency growth, and a 19.5%-20.5% core operating margin, reflecting softer surgical demand and tariff headwinds.

Key takeaways

  • Q2 sales were $2.6 billion, with Vision Care up 5% while the surgical franchise grew about 1%.
  • Management highlighted STAAR Surgical and LumiThera acquisitions alongside Unity VCS, PanOptix Pro, Precision7 and Tryptyr launches.
  • Tariff impact was estimated at about $100 million, with currency hedges and supply-chain actions cited as mitigations.

Management priorities

  • Integrate the STAAR and LumiThera additions and expand their portfolios.
  • Scale Unity VCS installations and continue global rollout of new products.
  • Pursue reimbursement and market expansion for Valeda and Tryptyr.

Follow ALC with an agent that reads every filing, transcript, and price print. Free to start.

Try FN2 free

Earnings History

Estimate Beat Miss Match
ALC REVENUE earnings history estimate and actual scatter chart 10 reported fiscal quarters and 4 future estimate-only quarters. Q1 '24 estimate $3B Q1 '24 actual $2B, miss Q2 '24 estimate $3B Q2 '24 actual $3B, miss Q2 '25 estimate $3B Q2 '25 actual $3B, miss Q3 '25 estimate $3B Q3 '25 actual $3B, miss Q4 '25 estimate $3B Q4 '25 actual $3B, miss Q1 '26 estimate $3B Q1 '26 actual $3B, beat Q2 '26 estimate $3B Q2 '26 actual $3B, beat Q3 '26 estimate $3B Q3 '26 actual $3B, beat Q4 '26 estimate $3B Q1 '27 estimate $3B Q2 '27 estimate $3B Q3 '27 estimate $3B
Show 2 more >

Analyst Consensus ?

ConsensusHold26 ratings
Bullish1453.8%
Neutral1038.5%
Bearish27.7%

Analyst 52W Price Targets

$74.31Current
$35Low
$87.16Average
$110High

Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Nov 22, 2026. Not an FN2 forecast.

Firm-level rating actions

FMP grade actions identify the grading firm, not a named analyst.

FirmRatingPrior ratingActionDate
Stifel Hold HoldMaintainNov 12, 2026
Barclays Equal Weight Equal WeightMaintainNov 12, 2026
Baird Outperform OutperformMaintainNov 12, 2026
Needham Buy BuyMaintainNov 11, 2026
BTIG Buy BuyMaintainNov 11, 2026
Show 21 more rating actions

Named analyst price targets

Upside is calculated against the persisted current price $74.31. FMP does not supply a rating on these named-analyst rows.

FirmAnalyst52W targetPrice when postedUpsideDate
BernsteinSusannah Ludwig$88.9$72.8 +19.6%Nov 12, 2026
NeedhamDavid Saxon$98$71.45 +31.9%Nov 2, 2026
KeyBancAnalyst unavailable$84$69.99 +13.0%Oct 27, 2026
BTIGAnalyst unavailable$74$64.14 -0.4%Oct 12, 2026
BarclaysChristopher Pasquale$70$63.19 -5.8%Oct 6, 2026
See 46 more

Track every rating change on ALC the moment it posts. Free to start.

Start free

Company context

Snapshot as of publication

Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. The company operates through two segments, Surgical and Vision Care. It offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. The company’s cataract products include Unity CS, LenSx laser system, Verion reference unit and Verion digital marker, ARGOS biometer, SMARTCATARACT health platform, NGENUITY 3D visualization system, LuxOR surgical ophthalmic microscope, and ORA system for intra-operative measurements; ADI cloud-based platform; and implantable products, including monofocal, Toric, and Presbyopia-Correcting IOLs, as well as delivery systems, such as…

Historical context

All ALC earnings

Healthcare peers this season

Latest reports in the same sector
CompanyQuarterEPS surpriseMarket moveHeadline
ASND Ascendis Pharma A/S FY2026 Q3 · Calendar Q4 2026 +38.7% +3.0% Ascendis Q3 growth broadens the story, while execution risks remain

Latest beats and misses

Who reports next

Get the ALC recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Sources

  1. Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
  2. FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
  3. Polygon adjusted daily market bars · 2026-10-06T23:40:45.137348+00:00
  4. Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-06T23:40:45.135502+00:00

Methodology

Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.

Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.

Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.

By FN2 Research · Updated · As of 2026-10-06. For educational purposes only; not investment advice.